Literature DB >> 29703719

Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.

Thomas J Boltje1, Natasja Balneger2, Christian Büll2, Sarah M Weischer2, Melissa Wassink2, Jasper J van Gemst3, Victor R Bloemendal1, Louis Boon4, Johan van der Vlag3, Torben Heise1, Martijn H den Brok2,5, Gosse J Adema6.   

Abstract

Sialic acid sugars on the surface of cancer cells have emerged as potent immune modulators that contribute to the immunosuppressive microenvironment and tumor immune evasion. However, the mechanisms by which these sugars modulate antitumor immunity as well as therapeutic strategies directed against them are limited. Here we report that intratumoral injections with a sialic acid mimetic Ac53FaxNeu5Ac block tumor sialic acid expression in vivo and suppress tumor growth in multiple tumor models. Sialic acid blockade had a major impact on the immune cell composition of the tumor, enhancing tumor-infiltrating natural killer cell and CD8+ T-cell numbers while reducing regulatory T-cell and myeloid regulatory cell numbers. Sialic acid blockade enhanced cytotoxic CD8+ T-cell-mediated killing of tumor cells in part by facilitating antigen-specific T-cell-tumor cell clustering. Sialic acid blockade also synergized with adoptive transfer of tumor-specific CD8+ T cells in vivo and enhanced CpG immune adjuvant therapy by increasing dendritic cell activation and subsequent CD8+ T-cell responses. Collectively, these data emphasize the crucial role of sialic acids in tumor immune evasion and provide proof of concept that sialic acid blockade creates an immune-permissive tumor microenvironment for CD8+ T-cell-mediated tumor immunity, either as single treatment or in combination with other immune-based intervention strategies.Significance: Sialic acid sugars function as important modulators of the immunosuppressive tumor microenvironment that limit potent antitumor immunity.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/13/3574/F1.large.jpg Cancer Res; 78(13); 3574-88. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29703719     DOI: 10.1158/0008-5472.CAN-17-3376

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.

Authors:  Renske J E van den Bijgaart; Michiel Kroesen; Melissa Wassink; Ingrid C Brok; Esther D Kers-Rebel; Louis Boon; Torben Heise; Monique van Scherpenzeel; Dirk J Lefeber; Thomas J Boltje; Martijn H den Brok; Peter M Hoogerbrugge; Christian Büll; Gosse J Adema
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

2.  Targeted self-destruction.

Authors:  Emily Rodrigues; Matthew S Macauley
Journal:  Nat Chem Biol       Date:  2020-12       Impact factor: 15.040

Review 3.  Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.

Authors:  Heinz Läubli; Ajit Varki
Journal:  Cell Mol Life Sci       Date:  2019-09-04       Impact factor: 9.261

4.  CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.

Authors:  Poornima Ramkumar; Anthony B Abarientos; Ruilin Tian; Meghan Seyler; Jaime T Leong; Merissa Chen; Priya Choudhry; Torsten Hechler; Nina Shah; Sandy W Wong; Thomas G Martin; Jeffrey L Wolf; Kole T Roybal; Andreas Pahl; Jack Taunton; Arun P Wiita; Martin Kampmann
Journal:  Blood Adv       Date:  2020-07-14

5.  Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma.

Authors:  Niels W C J van de Donk; Maria Themeli; Saad Z Usmani
Journal:  Blood Cancer Discov       Date:  2021-07

6.  CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.

Authors:  C Kimberly Tsui; Robyn M Barfield; Curt R Fischer; David W Morgens; Amy Li; Benjamin A H Smith; Melissa Anne Gray; Carolyn R Bertozzi; David Rabuka; Michael C Bassik
Journal:  Nat Chem Biol       Date:  2019-08-26       Impact factor: 15.040

7.  Targeted glycan degradation potentiates the anticancer immune response in vivo.

Authors:  Melissa A Gray; Michal A Stanczak; Natália R Mantuano; Han Xiao; Johan F A Pijnenborg; Stacy A Malaker; Caitlyn L Miller; Payton A Weidenbacher; Julia T Tanzo; Green Ahn; Elliot C Woods; Heinz Läubli; Carolyn R Bertozzi
Journal:  Nat Chem Biol       Date:  2020-08-17       Impact factor: 15.040

8.  Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.

Authors:  Itziar Ibarlucea-Benitez; Polina Weitzenfeld; Patrick Smith; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

9.  On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape.

Authors:  Stacy Alyse Malaker; Jusal Quanico; Antonella Raffo-Romero; Firas Kobeissy; Soulaimane Aboulouard; Dominique Tierny; Carolyn Ruth Bertozzi; Isabelle Fournier; Michel Salzet
Journal:  Cell Chem Biol       Date:  2021-06-07       Impact factor: 8.116

10.  Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma.

Authors:  Nan Xiao; Xiaodong Zhu; Kangshuai Li; Yifan Chen; Xuefeng Liu; Bin Xu; Ming Lei; Jiejie Xu; Hui-Chuan Sun
Journal:  Exp Hematol Oncol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.